Predictive analysis of ceftazidime hydrolysis in CTX-M-type beta-lactamase family members with a mutational substitution at position 167

Int J Antimicrob Agents. 2007 Mar;29(3):326-31. doi: 10.1016/j.ijantimicag.2006.09.014. Epub 2007 Jan 26.

Abstract

The CTX-M family of extended-spectrum beta-lactamases has been increasing in number over recent years. Its members preferentially hydrolyse cefotaxime over ceftazidime. Recently, ceftazidime-hydrolysing CTX-M beta-lactamase producers with a mutation at Pro167Ser have been found. The aim of this study was to determine whether members of the CTX-M-type beta-lactamase family are capable of ceftazidime hydrolysis after introduction of the Pro167Ser point mutation. MICs of wild-type enzyme producers for cefotaxime were 2-4 times higher than those of their respective Pro167Ser mutants, whereas MICs of wild-type enzyme producers for ceftazidime were 4-32 times lower than those of their respective Pro167Ser mutants. The k(cat)/K(m) values for Pro167Ser mutants and their respective wild-type enzymes were identical for cefalothin, penicillin and nitrocefin. For cefotaxime, catalytic efficiency (k(cat)/K(m)) for wild-type enzymes was 3.13-7.12 times higher than that of their respective Pro167Ser mutants. As these enzymes exhibit a very high K(m) value (>680 mM) for ceftazidime, we measured initial hydrolysis rates for each enzyme at a low substrate concentration (10 microM) to obtain their k(cat) and k(cat)/K(m) values. Under these conditions, Pro167Ser mutants had k(cat)/K(m) values 1.73-2.21 times higher than those of their respective wild-type enzymes. These results indicate that the CTX-M-type beta-lactamase family can hydrolyse ceftazidime more efficiently because of the point mutation at position 167.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Anti-Bacterial Agents / metabolism*
  • Anti-Bacterial Agents / pharmacology
  • Bacterial Proteins / genetics
  • Bacterial Proteins / metabolism
  • Base Sequence
  • Ceftazidime / metabolism*
  • Ceftazidime / pharmacology
  • DNA, Bacterial / genetics
  • Escherichia coli / genetics
  • Gram-Negative Bacteria / drug effects
  • Gram-Negative Bacteria / enzymology
  • Gram-Negative Bacteria / genetics
  • Hydrolysis
  • Kinetics
  • Mutagenesis, Site-Directed
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Transformation, Genetic
  • beta-Lactamases / classification
  • beta-Lactamases / genetics*
  • beta-Lactamases / metabolism*

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • DNA, Bacterial
  • Recombinant Proteins
  • Ceftazidime
  • beta-Lactamases